Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus.
about
The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolismModulating DDAH/NOS Pathway to Discover Vasoprotective Insulin SensitizersAutoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunityDimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginineFolic acid treatment normalizes NOS-dependence of vascular tone in the metabolic syndrome.The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study.Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control.Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic micePreventing a Cardiovascular Disease Epidemic among Indigenous Populations through Lifestyle Changes.Cardiovascular risk in patients with psoriatic arthritis.Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation.Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.Asymmetric dimethylarginine plasma levels and endothelial function in newly diagnosed type 2 diabetic patientsIntercellular Adhesion Molecule and Endogenous NOS Inhibitor: Asymmetric Dimethylarginine in Pregnant Women with Gestational Diabetes Mellitus.Effect of asymmetric dimethylarginine (ADMA) on heart failure development.Asymmetric dimethylarginine attenuates serum starvation-induced apoptosis via suppression of the Fas (APO-1/CD95)/JNK (SAPK) pathway.Evaluation of asymmetric dimethylarginine (ADMA) levels in children with growth hormone deficiency.Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin-Potential for Preventing or Slowing the Progression of Diabetic Complications.Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia.The role of asymmetric and symmetric dimethylarginines in renal disease.Examining the role of insulin in the regulation of cardiovascular health.Biological activities of guanidine compounds, 2008 - 2012 update.Cutaneous vasodilator and vasoconstrictor mechanisms in temperature regulation.The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases.L-Arginine and its metabolites in kidney and cardiovascular disease.A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations.Asymmetric dimethylarginine is transported by the mitochondrial carrier SLC25A2.Clinical phenotype, biochemical profile, and treatment in 19 patients with arginase 1 deficiency.Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.Anti-apolipoprotein A-1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis.Endothelial Dysfunction in Obesity.How does spa treatment affect cardiovascular function and vascular endothelium in patients with generalized osteoarthritis? A pilot study through plasma asymmetric di-methyl arginine (ADMA) and L-arginine/ADMA ratio.Blood asymmetric dimethylarginine and nitrite/nitrate concentrations in short-stature children born small for gestational age with and without growth hormone therapy.Asymmetric dimethylarginine (ADMA) is identified as a potential biomarker of insulin resistance in skeletal muscle.Reduced endothelial activation after exercise is associated with improved HbA1c in patients with type 2 diabetes and coronary artery disease.Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke.Determination of asymmetric dimethyl arginine in human serum by liquid chromatography-tandem mass spectrometry: clinical application in hypertensive subjects.Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease.Symmetric dimethylarginine (SDMA) serum levels in rheumatoid arthritis: correlations with insulin resistance and disease activity scores.Asymmetric dimethylarginine (ADMA) elevation and arginase up-regulation contribute to endothelial dysfunction related to insulin resistance in rats and morbidly obese humans.
P2860
Q24611412-22B2E14F-6799-4CEA-B7C9-C94E711FE62FQ26771754-5368B301-958F-4398-8A79-98DE4A4A500EQ27004493-9E5E2DC7-9571-49B3-BC60-DE029C7FF321Q28506246-A0E84611-CC2E-4ED0-833A-47CB8016934CQ33701506-EE2FAFD2-E32F-4FF0-83E8-3B5DDEEAE013Q34632841-BBEA2E25-7388-4024-9E57-8C9073BC3249Q34670457-B10619AC-9C7E-4C75-9D47-0284EF636BDFQ35153847-68C8DC3F-AA4E-41AB-BC6E-8AC2A4F0D769Q35966335-A17BF382-221F-41B6-9931-A711121C576AQ35974962-197CD4AA-F14B-4982-8411-CE2409FAAD9BQ36276126-16250753-3103-43DB-803D-BFD8FE16A669Q36396428-157C0F22-1BDD-4478-9623-072186EED329Q36432385-F584125F-B396-434E-A433-E486F2776F96Q36615377-4E704710-6A39-4D05-9E9A-0D4AA6ED90C3Q37245523-D3D415D5-B8AF-4FF4-B8B2-68D4868CF6A8Q37299599-3FD442D1-72FA-4C51-895B-383DA3D9F246Q37702780-2AE92E0F-F5B5-48C7-BB1A-3F7F4A7576C7Q37728038-A34A6949-04BD-4A9D-9ECE-49AFBDA3DCE0Q37850374-65028FA2-76B3-4A14-824A-494EEC1783C7Q37858880-C79E8B01-D31E-4B01-80EC-835A7359591EQ38069198-7C28C343-79AD-4DFE-9A5E-D3A26EA78D99Q38101620-21842678-E2B0-41AD-B616-AF7A398D4019Q38201379-78CBBCC1-6469-4790-B8D2-FCF7603A853AQ38203518-01A78882-A65F-4AFD-B687-5EBB0FE7B9E7Q38243758-BD2CC831-D569-447D-9E8E-E8FDF90AF2FCQ38477549-D146BAA0-9AFC-42E9-B4D3-F2068D8E65B4Q38832760-3E1EA4E2-B967-42BE-9A04-14BFFDEC28DAQ38886946-E077FE36-64C5-4720-9FE2-FAF7B208D3F1Q42513803-6618F3D4-67D3-4B0C-86E8-10D44DF06555Q45346743-F5CBBE4A-3FC2-47BA-B5F4-C4DCFC3FA5BDQ46355665-C11F8FFA-9403-45F9-B814-330F4381C830Q47197811-6B40B169-6437-4215-8215-1C9AC4AC5BB6Q48250482-0B38F0D4-7AD0-41B8-A7F5-0F2DF3D65A3CQ49202628-07BB16F8-7D56-404A-A38A-4C72A840EE4CQ50939730-914E3222-AEB3-472D-B1F9-A112692C4D74Q52891394-3A5B78F0-6DDE-46FB-899A-CB271899434CQ53088599-3C7588CF-7A1C-430A-AA9E-9D832AD1914AQ53548426-3D7E507B-0725-4F10-B01A-74485364FF5AQ53583233-AA0C347A-0303-46E3-AA50-AAEEAA0146B2Q53798961-43DD4A80-C4AB-4C42-90A1-A2336E77DA9F
P2860
Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Asymmetric dimethylarginine as ...... action with diabetes mellitus.
@en
Asymmetric dimethylarginine as ...... action with diabetes mellitus.
@nl
type
label
Asymmetric dimethylarginine as ...... action with diabetes mellitus.
@en
Asymmetric dimethylarginine as ...... action with diabetes mellitus.
@nl
prefLabel
Asymmetric dimethylarginine as ...... action with diabetes mellitus.
@en
Asymmetric dimethylarginine as ...... action with diabetes mellitus.
@nl
P2093
P2860
P356
P1476
Asymmetric dimethylarginine as ...... action with diabetes mellitus.
@en
P2093
Edzard Schwedhelm
Maike Anderssohn
Nicole Lüneburg
Rainer H Böger
P2860
P304
P356
10.1177/1479164110366053
P407
P577
2010-03-17T00:00:00Z